1. Antibody–drug conjugates for lung cancer in the era of personalized oncology
   Biagio Ricciuti et al, 2021, Seminars in Cancer Biology CrossRef
2. Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
   Rebecca Suk Heist et al, 2017, Journal of Clinical Oncology CrossRef
3. Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
   Ticiana Leal et al, 2023, Expert Review of Anticancer Therapy CrossRef
4. Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
   Shutan Liao et al, 2021, Drug Development Research CrossRef
5. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)
   Claudia Parisi et al, 2023, Cancer Treatment Reviews CrossRef
6. The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon
   Yasar Ahmed et al, 2021, Oncology CrossRef
7. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
   David M. Goldenberg et al, 2018, Oncotarget CrossRef
8. Clinical impact of TROP2 in non‐small lung cancers and its correlation with abnormal p53 nuclear accumulation
   Remi Mito et al, 2020, Pathology International CrossRef
9. Flot-2 Expression Correlates with EGFR Levels and Poor Prognosis in Surgically Resected Non-Small Cell Lung Cancer
   Qiuyuan Wen et al, 2015, PLOS ONE CrossRef
10. Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer
    Lorenzo Belluomini et al, 2023, Expert Opinion on Biological Therapy CrossRef
11. Trop2: Jack of All Trades, Master of None
    Sára Lenárt et al, 2020, Cancers CrossRef
12. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments
    Joshua E. Reuss et al, 2021, Clinical Lung Cancer CrossRef
13. siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells
    XIAO-YAN GAO et al, 2015, Experimental and Therapeutic Medicine CrossRef
14. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer
    Xinlin Liu et al, 2022, Pharmacology & Therapeutics CrossRef
15. Novel Formulations and New Mechanisms of Delivering Chemotherapy
    Thomas E. Stinchcombe, 2014, American Society of Clinical Oncology Educational Book CrossRef
16. The Role of TROP2 in BCC and Cutaneous SCC: A Clinical and Immunohistochemical Study
    Azza Gaber Antar Farag et al, 2021, Clinical, Cosmetic and Investigational Dermatology CrossRef
17. Antibody-drug conjugates in lung cancer: dawn of a new era?
    Niamh Coleman et al, 2023, npj Precision Oncology CrossRef
18. Incorporation of CD40 ligand enhances the immunogenicity of tumor‑associated calcium signal transducer 2 virus‑like particles against lung cancer
    Wang Xi et al, 2018, International Journal of Molecular Medicine CrossRef
19. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC
    Benjamin P Levy et al, 2023, Future Oncology CrossRef
20. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
    Melissa Johnson et al, 2022, Lung Cancer CrossRef
21. Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model
    Yitian Wu et al, 2024, EJNMMI Radiopharmacy and Chemistry CrossRef
22. Trophoblast cell surface antigen 2 expression predicts outcome in oral squamous cell carcinomas
    Mauricio Rocha Dourado et al, 2022, Oral Diseases CrossRef
23. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
    Thomas M. Cardillo et al, 2015, Bioconjugate Chemistry CrossRef
24. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments
    Shota Omori et al, 2022, Journal of Cancer Research and Clinical Oncology CrossRef